

Special Issue

Angiogenic Growth Factors in Tumor Development: Beyond New Blood Vessels Formation

Message from the Guest Editors

Accumulating evidence indicates that angiogenic growth factors (AGFs) are involved in tumor growth and progression via multiple mechanisms that go beyond their angiogenic role. Indeed, within the tumor microenvironment (TME), AGFs produced by tumor and inflammatory cells create a tolerogenic milieu that allows the escape of cancer cells from immune recognition and elimination. Therapeutic strategies targeting AGFs to restore vessel normalization have been found to improve antitumor immunity and, in turn, immune-mediated mechanisms can regulate the response to antiangiogenic therapy. In this Special Issue we welcome the submission of reviews, mini-reviews, and original research articles that can offer new insights into the following topics:

- The multifaceted relationship between AGFs and cells of innate and adaptive immunity in the TME;
- Reciprocal interplay between immune cell types in a TME characterized by AGFs upregulation;
- Role of AGFs in endothelial-immune cell cross-talk during vascular inflammation and metastasis;
- Prediction and optimization of cellular responses to therapeutic strategies based on AGF-targeting agents and immune-checkpoint inhibitors.

Guest Editors

Dr. Loredana Albonici

1. Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy
2. Department of Biomedical Sciences, "Our Lady of Good Counsel" University, Rruga Dritan Hoxha, 1000 Tirana, Albania

Dr. Camilla Palumbo

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/132820

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).